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We present the first validated metabolic network model for analysis of flux through
key pathways of tumor intermediary metabolism, including glycolysis, the oxidative and
non-oxidative arms of the pentose pyrophosphate shunt, the TCA cycle as well as its
anaplerotic pathways, pyruvate–malate shuttling, glutaminolysis, and fatty acid biosyn-
thesis and oxidation. The model that is called Bonded Cumomer Analysis for application
to 13C magnetic resonance spectroscopy (13C MRS) data and Fragmented Cumomer
Analysis for mass spectrometric data is a refined and efficient form of isotopomer
analysis that can readily be expanded to incorporate glycogen, phospholipid, and other
pathways thereby encompassing all the key pathways of tumor intermediary metabolism.
Validation was achieved by demonstrating agreement of experimental measurements of
the metabolic rates of oxygen consumption, glucose consumption, lactate production,
and glutamate pool size with independent measurements of these parameters in cultured
human DB-1 melanoma cells. These cumomer models have been applied to studies of
DB-1 melanoma and DLCL2 human diffuse large B-cell lymphoma cells in culture and as
xenografts in nudemice at 9.4 T. The latter studies demonstrate the potential translation of
these methods to in situ studies of human tumor metabolism by MRS with stable 13C iso-
topically labeled substrates on instruments operating at high magnetic fields (7 T). The
melanoma studies indicate that this tumor line obtains 51% of its ATP by mitochondrial
metabolism and 49% by glycolytic metabolism under both euglycemic (5mM glucose)
and hyperglycemic conditions (26mM glucose). While a high level of glutamine uptake
is detected corresponding to ~50% of TCA cycle flux under hyperglycemic conditions,
and ~100% of TCA cycle flux under euglycemic conditions, glutaminolysis flux and its
contributions to ATP synthesis were very small. Studies of human lymphoma cells demon-
strated that inhibition of mammalian target of rapamycin (mTOR) signaling produced
changes in flux through the glycolytic, pentose shunt, and TCA cycle pathways that were
evident within 8 h of treatment and increased at 24 and 48 h. Lactate was demonstrated
to be a suitable biomarker of mTOR inhibition that could readily be monitored by 1H MRS
and perhaps also by FDG-PET and hyperpolarized 13C MRS methods.
Keywords: metabolic modeling, sensitivity analysis, cancer metabolism, isotopomer, metabolic flux analysis,
isotopolome, 13C magnetic resonance spectroscopy, 13C liquid chromatography-mass spectrometry
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INTRODUCTION
Tumor intermediary metabolism provides the energy required
to sustain cancer cells over their entire life span. This energy
is utilized to maintain cation pumps, including the pumps that
eliminate cytotoxic drugs contributing to multi-drug resistance.
It also provides energy for cellular motility during metastasis.
Tumor metabolism also provides key metabolic precursors for
DNA, protein, and lipid synthesis during cellular replication.
Delineation of flux through these critical metabolic pathways pro-
vides an invaluable tool, complementary to genomic information,
for cancer diagnosis as well as prediction and early detection of
therapeutic response. Tracing these metabolic pathways was first
accomplished through the use of radioactive isotopic labels, but
monitoring of flux through these pathways has more recently
been achieved by analysis of stable 13C isotope kinetics labeling
detected with metabolomic tools – magnetic resonance spec-
troscopy (MRS) and liquid chromatography–mass spectrometry
(LC–MS) – the former providing a potentially non-invasive but
relatively insensitive method for imaging metabolism and the
latter providing a much more sensitive but invasive approach.
Analysis of these dynamic isotopolome (labeled metabolome)
data used to require solution of hundreds of differential equations
that could only be accomplished with the help of supercomputers
(1), but today can be readily accomplished with laptop computers
virtually in real time. This problem has been solved for normal
organs, such as the heart (1–6), brain (7–9), and liver (10–12); our
goal here is to describe the first validated solution of the problem
for tumors.
We present data on human DB-1 melanoma and models of
various non-Hodgkin’s lymphomas (NHLs). DB-1 melanoma has
served as the principal tumor model on which this technology
has been developed and validated (13, 14). This technology has
been applied to isolated perfused tumor cells grown ex vivo as
monolayers on solid microcarrier beads in a bioreactor system
or in flasks and to in vivo xenografts in mice. Isotope exchange
has been monitored non-invasively in vivo or in intact cells by
13C MRS and invasively by LC–MS following ex vivo extraction.
The NHL models have been examined by similar methods except
that because they are anchorage independent, they had to be
immobilized by encapsulation in agarose beads or studied in batch
suspension culture. Encapsulation of cells in agarose or alginate
beads invariably introduces heterogeneity in the cellular microen-
vironment, a problem that can be overcome by growth in batch
culture from which aliquots are isolated for periodic analysis.
The goal is to lay the groundwork for performing these measure-
ments non-invasively on human patients who will be monitored
in high-field (7 T) spectrometers before and following treatment
Abbreviations: AA, amino acids; ASCT2, alanine-serine-cysteine (GLN) trans-
porter 2; BC, Bonded Cumomer; CEST, chemical exchange saturation-transfer;
CMR, cellular metabolic rate; CMRatp, ATP production rate; CMRlac, Lactate
production rate; FA, fatty acid; GLUT, glucose transporter; h, hours; IDH, isocitrate
dehydrogenase; MCT, monocarboxylic acid transporter; MID, mass-isotopomer
distribution;MRO2, O2 consumption rate; oxphos, oxidative phosphorylation; PPP,
pentose phosphate pathway; P/O, phosphate to oxygen ratio; RC, reductive carboxy-
lation; SGOC, serine glycine one carbon metabolism; TCA cycle, tricarboxylic acid
cycle.
with appropriate therapeutic agents whose choice will be at least
partially dictated by metabolic flux analysis of tumors following
administration of appropriate 13C-labeled substrates. Changes in
tumor metabolism indicated by these labeling experiments will
point to the probable success or failure of drug delivery and will
monitor the effect of these agents on tumor metabolism.
Non-Hodgkin’s lymphoma tumors have served as models
for developing methods for monitoring response to signal-
transduction pathway inhibitors (15) as well as response to more
conventional drug combinations, such as RCHOP [Rituximab,
Cyclophosphamide, doxorubicin hydrochloride (Hydroxydauno-
mycin), vincristine sulfate (Oncovin), and Prednisone (16, 17)].
In this review, we will focus on studies of mammalian target
of rapamycin (mTOR) inhibitors as representative of the former
class of targeted therapeutic agents. Drugs that are inhibitors of
signal-transduction pathways are generally more cytostatic rather
than cytotoxic and usually do not exhibit significant changes in
tumor volume except very late in the course of therapy. For these
drugs, monitoring their effect on tumor metabolism may prove
to be the most efficient approach to detect therapeutic response.
Since 13C metabolomics/isotopolomic studies are expensive and
labor intensive, it may prove advantageous to identify surrogate
biomarkers of therapeutic response whose metabolism could be
followed by more conventional methods, such as lactate imaging
by 1H MRS or 1H chemical exchange of saturation-transfer (1H
CEST), hyperpolarized 13C MRS or PET/CT with FDG or other
appropriate metabolic probes. This two-stage approach – utilizing
13C MRS for initial exploration of overall tumor metabolism and
identification of suitable biomarkers for subsequent follow-up by
1H MRS or other appropriate method – is a general strategy that
we are proposing for monitoring signal-transduction inhibitors.
The feasibility of achieving this “personalized medicine dream”
or at least the 13C MRS exploratory phase is already demon-
strated through the pioneer work of investigators at the University
of Texas Southwestern, who have monitored the metabolism of
13C-labeled substrates by ex vivo analysis of surgical specimens
obtained from patients with brain (18) and lung (19) tumors.
Studies of human tumor xenografts in mice detected by 13CMRS
(see below) will further demonstrate the potential feasibility of
non-invasive monitoring of tumor metabolism. The purpose of
this manuscript is to describe the technical details on how 13C
isotope kinetics can be monitored and quantitatively analyzed.
BACKGROUND
Types of 13C MRS Experiments
Following administration of 13C-labeled substrates, one can mon-
itor the time course of distribution of the isotopic label among the
various metabolites of the substrate either directly by 13C MRS
or indirectly through 1H MRS of the protons directly bonded
to the isotopically labeled carbon atoms. These methods have
been extensively reviewed by de Graaf et al. (20) and will not be
considered further here except to note their key advantages and
limitations. Direct detection offers the advantage of simultane-
ously monitoring all the sites of isotopic substitution, but signal
intensity will depend on the detection coil, the method used for
proton decoupling as well as on the pulse sequence that is used
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for 13C excitation. Broadband decoupling, the method that we
have employed, will simultaneously decouple all the protons and
will produce nuclear Overhauser enhancements (NOE) that will
depend on relaxation times, the fraction of the relaxation occur-
ring through dipolar mechanisms and the broadband decoupling
technique (e.g., MLEV and WALTZ). There will be differences
in signal enhancement, and these will have to be calibrated. For
in vivo applications, the NOEs vary between 1.3 and 2.9 for pro-
tonated carbons, and are 1.0 for unprotonated carbons or carbons
that relax by non-dipolar mechanisms. Alternatively, one could
use dynamic polarization-transfer excitation for direct 13C excita-
tion (21, 22); this method requires quantum mechanical density
matrix or product-operator analysis for quantitative interpreta-
tion, which is beyond the scope of this manuscript. In general, the
direct excitation methods, delineated as 13C-{1H}, are less sensi-
tive than the indirect detection techniques, 1H-{13C}, by which the
protons directly bonded to the isotopically labeled carbon atoms
are monitored with the 13C magnetization being manipulated
either by simple subtraction of multiple experiments, by multiple
quantum coherence transfer or by J-difference pulse sequences
that depend on spin–spin coupling (20). Another key consider-
ation in these experiments is the issue of power deposition or
sample heating, which becomes limiting in the inverse-detection
techniques when broadband decoupling of carbon resonances is
applied and also depends on coil design and various other factors.
While we note the potential signal enhancing possibilities that
can be achieved with indirect detection, most investigators, and
our group included, utilize simple direct 13C-{1H} detection with
broadband decoupling at least as a starting point for MRS studies
of 13C isotope exchange kinetics.
Metabolic Flux-Analysis Models
Metabolic flux-analysis dates back to the classic study published
in 1983 by Chance, Seeholtzer, Kobayashi, and Williamson at the
University of Pennsylvania and University College London, on
flux through the tricarboxylic acid cycle (TCA cycle) in Lan-
gendorff perfused rat hearts (1). These investigators sacrificed
large numbers of rats, excised their hearts, mounted them in a
Langendorff retrograde perfusion apparatus, perfused the hearts
with various 13C enriched substrates ([3-13C] pyruvate or [2-
13C] acetate), freeze clamped the hearts at various time points,
extracted the water soluble metabolites with perchloric acid, and
analyzed the extracts with direct 13C-{1H} MRS to measure the
time course of isotopic labeling of glutamate, alanine, and aspar-
tate. The datawere fit by least-squares analysis to an idealizedTCA
cycle model consisting of oxaloacetate in equilibrium with aspar-
tate, citrate, α-ketoglutarate, and reactions involving glutamate,
succinate, andmalate. The analysis required about 325 differential
equations that were solved with the aid of a Cray supercomputer.
The model fit estimates of isotope enrichment of carbon atoms in
glutamate and aspartate, and calculated the rate of TCA cycling,
but did not attempt to validate this rate. This was accomplished
later by Chatham et al. (2), who calculated the metabolic rate
of oxygen consumption (MRO2) from the rate of production of
reducing equivalents assuming that the systemwas at equilibrium.
They compared the calculated rate with the experimental rate
measured with oxygen electrodes placed at the inlet and outlet
ports of the Langendorff perfusion apparatus; MRS and MRO2
data acquisition were performed directly in the magnet on the
beating heart, and the mathematical fitting was performed with
a simple laptop computer. The results demonstrated that the orig-
inal model proposed by Chance et al. (1) consistently predicted
MRO2 values that were significantly below the experimentally
measured rates. The error was attributed to the absence of the
shuttles in the TCA cycle model; inclusion of the malate-aspartate
and glycerophosphate shuttles in the model led to perfect agree-
ment between experimental andmodel-predicted data.We believe
that this was the first validated isotope enrichment model.
In 1994, Sherry and Malloy and coworkers at Dallas South-
western (23) introduced a considerably more efficient method,
isotopomer analysis, which took into account multiple sites of
isotope labeling and substantially simplified the mathematics of
analysis of the kinetics of isotope labeling. This method was first
employed to measure relative rates of anaplerotic vs. TCA cycle
flux in the heart and was later extended tomonitormore extensive
metabolic pathways in various organs, including liver (24–30) and
brain (31–42). Comparison of experimental and predicted MRO2
values validated the cardiac isotopomer analysis model of Jeffrey
et al. (3).
The motivation for developing additional theoretical frame-
work to study the fluxome (13) came from the challenges of
modern metabolic flux analysis. The details of flux analysis based
on cumomers were introduced in Ref. (43). Alternative cumomer
methods, such as elementary metabolite units (44), aim to min-
imize the dimension of variables space and to reduce the cost of
computation.
More recently, Shestov and colleagues introduced bonded
cumomer analysis at the University of Minnesota, where research
focused primarily on the brain (45), and later at the University
of Pennsylvania, where tumors were the central focus of research
(14, 46). Cumomer analysis is a more efficient method of gen-
erating the various isotopomer equations. Two variants of the
cumomer method are still under development, bonded cumomer
analysis, which applies to the analysis of 13C MRS data (14, 46),
and fragmented cumomer analysis (47–49) that analyzes LC–MS
data. The relative efficiency of the cumomer methods is perhaps
best illustrated by the fact that the original study of TCA cycle
metabolism of the heart using a model that lacked inclusion of
the two shuttles required about 325 differential equations to solve,
whereas the current bonded cumomer model describing about 10
pathways of tumor intermediary metabolism including the TCA
cycle and the pentose phosphate pathway are accomplished with
~210 differential equations that can be solved virtually in real time
with an ordinary laptop computer.
Types of 13C Metabolic Models
Metabolic isotope kinetic models can be subdivided into steady-
state and dynamic models, with the former analyzing measure-
ments of isotope distribution after isotopic steady state has been
established and the latter requiring a complete kinetic study.
The kinetic analysis is much more demanding and is yet to be
achieved in the clinical arena (18, 19). Steady-state measurements
can only measure relative rates, normalized to some standard
reference rate, such as TCA cycle flux, whereas the true kinetic
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measurements yield absolute fluxes through individual metabolic
pathways. Steady-state measurements can often be made on sur-
gically excised or biopsy derived specimens, and in the case of
MRS measurements, their signal-to-noise ratio can be enhanced
by long-term signal averaging, but kinetic measurements have
to be performed non-invasively in real time by MRS studies of
isolated perfused cells grown in a suitable bioreactor contained in
theNMR spectrometer or by non-invasiveMRSmeasurements on
living animals or humans. Alternatively, one can perform kinetic
experiments by periodically sampling cells or extracts from a liv-
ing host or from a bioreactor system. Both types of measurements
may eventually prove useful in the clinic, but the hope is that high-
fieldMRS will for the first time enable totally non-invasive studies
of human subjects. Dynamic nuclear polarization already enables
performance of true kinetic measurements in living animals and
even in humans, but to date this has not been accomplished at
normal in vivo concentrations; instead, ex vivo injections of much
higher concentrations of isotopically labeled hyperpolarized spec-
imens, most often labeled pyruvate have been utilized and moni-
tored within about a minute in real time. The relationship of such
studies to actual in vivometabolism is the subject of considerable
controversy and debate that requires further investigation. Even if
suchmethods distort in vivometabolism, theymight still be useful
for clinical diagnosis and monitoring of disease and therapy.
Mass Spectrometric Studies of Tumor
Metabolism
For dynamic isotopic labeling, DB-1 cells were cultured in
glutamine-free DMEM containing 2mM [U-13C5,15N2] glu-
tamine supplemented with 10% fetal bovine serum. After 0,
0.5, 1, 2, 4, and 6 h of incubation, medium was aspirated and
cells were snap frozen on dry ice. For comparing euglycemic
vs. hyperglycemia conditions, cells were labeled with glutamine-
free DMEMcontaining 2mM [U-13C5,15N2] glutamine and 5mM
glucose or 25mM glucose for 8 h. LC–MS analysis of isotopic
labeled metabolites was performed as previously described (47).
The Metabolic Network Model
We have utilized a novel three-compartment metabolic net-
work model with the bionetwork schematically depicted in
Figure 1 to calculate fluxes through key pathways of tumor energy
metabolism from 13C isotopic labeling data. This model includes
the perfusion medium, cytosolic and mitochondrial compart-
ments interconnected by various transporters, carriers, and
enzymes that span adjacent compartments. The model is appli-
cable to bioreactor systems and to in vivo data. Glucose (GLUT),
monocarboxylic acid (MCT), and glutamine (GLN) transporters
to the cytosolic compartment are included in the cytosolic mem-
brane. Tumors generally express GLUT1 and GLUT3, but only
GLUT1 is currently included in the model; similarly DB-1 con-
tains MCT1 and MCT4 in approximately equal proportions (50),
but since theKM ofMCT1 is approximately one-fifth that ofMCT4
(51–53), we have only includedMCT1. Because of the critical role
of glutamine in tumor energetics and metabolism, we have also
included the GLN transporter (ASCT2). This model can readily
be extended to incorporate other isoforms of MCT and GLUT as
well as transporters for other amino acids (AAs) and metabolites.
The following metabolic pathways are included in the network:
glycolysis, TCA cycle, α-ketoglutarate–glutamate, and oxaloac-
etate–aspartate exchange through the malate-aspartate shuttle,
anaplerosis through (a) pyruvate carboxylase (PC) activity, (b) at
the succinyl-CoA level, and (c) glutaminolysis throughmitochon-
drial glutaminase (GLS and GLS2), pyruvate recycling through
cytosolic (ME1) andmitochondrialmalic enzymes (ME2+ME3),
lactate dehydrogenase (LDH) activity, and transport processes.
Oxidative and non-oxidative branches of the pentose phosphate
pathway (PPP) fluxes were included in the modeling analysis as
well as de novo lipogenesis and fatty acid (FA) oxidation.
In order to permit access of pyruvate to the pyruvate dehydro-
genase complex (PDH) complex for conversion to acetyl-CoA and
incorporation into the TCAcycle, we have included themitochon-
drial pyruvate carrier (MPC), which was recently identified in all
mammalian cells (54–56). Pyruvate is also linked to the TCA cycle
via PC. The cytosolic compartment with direct links through the
mitochondria to the TCA cycle also contains citrate, glutamate,
andmalate. As noted above, themitochondrial compartment con-
tains the complete TCA cycle with links to the cytosol for citrate
and malate. α-Ketoglutarate is linked to glutamate via glutamate
dehydrogenase (GLUD) and two aminotransferases, aspartate
aminotransferase (GOT), and alanine aminotransferase (GPT).
In order to fit 13C time courses of labeled lactate, glutamate
and FAs to determine the corresponding metabolic fluxes and the
transport parameter for bidirectional lactate transport through the
cell membrane, we constructed a BC dynamic model adapted to
perfusion bioreactor experiments. In themodel, the perfused [1,6-
13C2] glucose and glutamine (labeled in some experiments, see
below) are transported from the extracellular medium to the DB-
1 cells. Reversible non-steady-state Michaelis–Menten facilitative
transport kinetics are assumed to occur through glucose (GLUT
family) or glutamine (ASCT2) transporters:
Jtri =
Jmaxtr

Mei
Ktrmi
  MiKtrmi

1+ MeiKtrmi +
Mi
Ktrmi
; (1)
where Jtri is the net transport flux for boundary species i between
media and cytosol or cytosol and mitochondria; Mei is the extra-
cellular concentration for species i, Jmaxtr is the maximal transport
rate, and Ktrmi is the Michaelis–Menten constant for transport.
Labeled lactate from the cell is transported into the mediumwhile
obeying Michaelis–Menten kinetics through the monocarboxylic
acid transporter (MCT family). Facilitated media-cell transport is
assumed for glucose, lactate, and glutamine.
Two types of mass balance equations for chemical and isotope
variables were expressed mathematically using the mass balance
equation for the total metabolite concentration in the medium,
cytosol, and mitochondria:
dMi
dt = J
tr
i +
X
j
νpji Fpji  
X
k
νuki Fuki ; (2)
where Mi is the intracellular concentration of the i species, Jtri is
the net transport flux for boundary species i between media and
cytosol or cytosol and mitochondria, Fpji and Fuki are the normal-
ized reaction fluxes that produce (j) or utilize (k) cellular species i,
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FIGURE 1 | Studied melanoma bionetwork: glycolysis, PPP, TCA cycle, α-ketoglutarate-glutamate, and oxaloacetate-aspartate exchange through
the malate-aspartate shuttle, anaplerosis through (a) pyruvate carboxylase activity, (b) succinyl-CoA, and (c) glutaminolysis through mitochondrial
glutaminases (GLS and GLS2); pyruvate recycling through cytosolic (ME1) and mitochondrial malic enzymes (ME2), lactate dehydrogenase activity,
de novo fatty acid synthesis, and transport processes. Metabolic flux map and energy metabolism with predicted oxygen consumption rate MRO2 in the
human melanoma DB1 bionetwork at hyperglycemia and normoxia. Numbers indicate fluxes in millimoles per liter-cell per hour. See Table 1 for definitions and values
of the derived fluxes.
and νpji and νuki are the corresponding stoichiometric coefficients.
The following general dynamic mass balance equations were used
to describe the extracellular boundarymetabolites in themedium:
dMe
dt = rie  J
tr
i ; (3)
where extracellular species concentration isMe, and rie is the ratio
of cell volume to media volume. We also included an additional
term for the medium flow rate. Note that we do not assume here
that media boundary metabolites are at constant concentration.
Bonded Cumomer Analysis
One can monitor flux through the biochemical network model
by measuring changes in isotopic enrichment of individual car-
bons in a molecule containing N carbon atoms. This yields a
total of N-independent time-courses or steady-state values. How-
ever, by considering all the different combinations of labeled and
unlabeled carbons, isotopomer models take full advantage of the
biochemical information that can be obtained from the NMR
spectra, yielding a total of 2N  1 independent variables for a
molecule with N different carbon atoms. Because not all possible
isotopomers are detectable byNMR, amodel including all possible
isotopomers would be unnecessarily complex. The concept of
bonded cumomers leads to a reduced number of equations as well
as a more simple derivation of these equations compared to a
model, including all possible istopomers, while retaining all the
NMR measureable isotopomer information.
Let M{i} denote the isotopomer of a metabolite M, where {i} is a
set of integers i1, i2,: : :, in indicating the positions of all the labeled
carbons. We refer to m{i} as the isotopomer fraction [M{i}]/[M] of
molecules M labeled exactly at positions i1, i2: : :, in. A cumulative
isotopomer fraction (or cumomer fraction), noted as pM{i} is by
definition, the sum of isotopomer fractions for all isotopomers
labeled at least at positions i1, i2: : :, in, whatever the label at the
other positions. We refer to the size n of the set {i} as the order of
Frontiers in Oncology | www.frontiersin.org June 2016 | Volume 6 | Article 1355
Shestov et al. Cumomer Analysis of Cancer Cell Metabolism
the p-function. For example, assuming that M has a total of four
carbons, the second order p-function pM{1,3} can be expressed as:
pMf1;3g = mf1;3g + mf1;2;3g + mf1;3;4g + mf1;2;3;4g (4)
For example, the cumomer fraction pM{1,3} for cumomerM{1,3}
is the probability that both the first and third carbon atoms of
this molecule are labeled. Shestov et al. (45) have presented a
complete exposition of the bonded cumomer formalism. Here, we
will present examples of how this formalism can be utilized to
efficiently monitor flux through the various metabolic pathways
in Figure 1 in various types of perfused cells and in xenografts
of these tumor cells in immunosuppressed mice. These examples
illustrate the type of information that can be obtained from similar
dynamic studies performed on human tumors in situ or from
extracts of biopsy or surgically excised freeze-clamped specimens
of these tumors measured at isotopic steady state.
Isotopomer dynamics of this system together with the initial
metabolome state vector M0 2 RN and fluxome Fo 2 RM (sub-
script “0” refers to baseline steady-state values and reaction rates)
are formulated as an initial value problem for ordinary differential
equations (ODE) in terms of Bonded Cumomer fractions as the
state variables. Metabolite 13C cumomer mass balance for parallel
monomolecular reactions was expressed in the form:
[M]
dπ(i)
dt =
X
j
Fjπσj(i)  
 X
k
Fk
!
π(i); (5)
where metaboliteM with pool size [M] is downstream of metabo-
lites Sj. While π(i) and πσj(i) represent the ith cumomer frac-
tion of metabolite M and metabolite Sj (i Bonded Cumomer),
respectively. The total outflux ΣFk balances influx ΣFj.
Shestov and coworkers (45) have described how isotopomer
balance equations have been derived for every metabolite Bonded
Cumomer of orders 1, 2, 3 (e.g., glutamate, glutamine, aspartate).
This resulted in a set of ~210 differential equations with fine
structure multiplets completely described by each metabolite’s
Bonded Cumomers of order 1, 2, and 3. Wiechert et al. (43) first
proposed the term cumomer, and the concept of cumomer was
used by Muzykantov and Shestov (57) in early studies. There are
connection matrices between the “Bonded Cumomer” π vectors
(which reflect subsets of metabolite isotopomers) and the vec-
tors of “fine structure” multiplets of 13C NMR spectra (singlets,
doublets, triplets, and quartets of 13C-labeled metabolite). Using
matrix connection equations, one derives kinetic equations in the
form of fine-structure spectroscopic-defined NMR data.
The fitted time-courses for [1,6-13C2] glucose perfusion were:
Glu4Tot (Tot-total), Glu4s, Glu4d34, Glu3Tot, Glu3d, Glu2Tot,
Glu2s, Lac3Tot, and acyl methylene (–(CH2)n–) resonance, for
a total of nine curves from which we determined the following
free fluxes: melanoma TCA cycle FTCA, PC FPC, exchange between
glutamate and α-ketoglutarate FX, anaplerotic exchange and net
flux at the level of SucCoA, FANA, mitochondrial malic enzyme
(ME2+ME3) activity, de novo FA production, glutaminolysis,
aspartate efflux, and three other parameters – Michaelis–Menten
lactate transport VLACmax and KLACm and total cellular lactate concen-
tration. Based on flux balance analysis including non-oxidative
glycolytic flux CMRlac and others, we also calculated other
fluxes and parameters, including the Warburg parameter (ratio
of flux from pyruvate to lactate vs. pyruvate to the MPC).
Using the Runge–Kutta fourth-order procedure for stiff sys-
tems in terms of Bonded Cumomers, we solved these differ-
ential equations to obtain time courses for all possible fine
structure 13C multiplets of glutamate, glutamine, and aspartate.
Minimization of the cost function was performed using Broy-
den–Fletcher–Goldfarb–Shanno or Simplex algorithms. By veri-
fying that goodness-of-fit values were close to expected theoretical
values, we confirmed proper mean-square convergence. Monte
Carlo simulations with experimental noise levels were used to
calculate parameter errors (58). All numerical procedures were
carried out in Matlab (Mathworks, Natick, MA, USA).
Liquid chromatography-mass spectrometry data without
detailed flux analysis were utilized to compare fluxes under
different conditions (e.g., hyperglycemia vs. euglycemia) since no
statistically significant change was observed between the different
medium glucose concentrations.
Metabolic Isotopomer Control Analysis for
Bonded Cumomer Models
Metabolic control analysis (MCA) was originally proposed to
quantify sensitivity – i.e., to measure the effect of changes in
any parameter of a system on the other variables in that system.
This approach was developed independently by two groups in the
1970s (59, 60) and has been limited to systems at steady state.
In this approach, the sensitivity of changes in variables, such as
metabolite concentrations due to changes in other parameters is
quantified by control coefficients. Metabolic control coefficients
are used for comparison of many parameters that span several
orders ofmagnitude. A control coefficient is defined as the relative
change in the variable per relative change in the parameter, when
infinitesimal changes are introduced:
CRp =

@R=R
@p=p

ss
=

@lnR
@lnp

ss
; (6)
where p is varied parameter and R is a system response, e.g.,
concentration or flux; the subscript ss indicates steady state. Sensi-
tivity analysismeasures the robustness of themetabolicmodel and
network topology to variations in parameter values. The robust
parameters with greatest influence on model simulation can help
to identify critical fluxes and pathways. These fluxes also have
less experimental error. Here, we extend the MCA technique to
dynamic metabolic flux analysis in which the behavior of interest
occurs in the temporal responses. First, we introduce the dynamic
isotopomer control coefficient or the sensitivity function:
ICCik =

@π(i)=π(i)
@Fk=Fk

; (7)
where π(i) represents the ith cumomer fraction of metabolite M,
and Fk is a certain parameter, such as a flux. By introducing these
variables, isotopomer sensitivity equations can be derived by dif-
ferentiating dynamic bonded cumomer balance equations (Eq. 5)
with respect to identified fluxes or other parameters that yield
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the corresponding initial value Cauchy problem for non-linear
ODE. The dynamic sensitivity equations determine the time evo-
lution of isotopomer control coefficients. These consist of a large
number of equations that must be solved simultaneously with the
initial system (1) resulting in double the number of differential
equations. These characteristics of the output sensitivity matrix
with respect to the flux vector F and other parameters provide
a framework for analysis of isotopomer model robustness. By
simulating the dynamic time course of sensitivity functions, one
identifies the fluxes most sensitive to a particular bonded cumo-
mer of a metabolite and 13C fine structure multiplet. Figure 2A
displays calculated values of those dynamic isotopomer control
coefficients (or relative sensitivity functions).
We also computed the sensitivity of the mean squared differ-
ence between experimental and correspondingmodel output (i.e.,
error) to finite changes in parameter values. The sensitivity to each
parameter was calculated as the relative change in mean squared
error (MSE) due to 5% change in the given parameter value:
Si =
max j(E (pi  0:05pi)  E (pi))j
0:05pi
pi  E (pi)
; (8)
where E represents the minimum mean squared difference
between model simulation and experimental data. These sensi-
tivity values represent the degree to which the theoretical curves
are sensitive to the value of individual parameters. High values of
the sensitivity parameter Si indicate that changing a parameter pi
results in a significant change in the simulated curves and in the
MSE E.
Figure 2B shows calculated MSE sensitivities for several free
fitted fluxes.
Applications of Metabolomics to
Melanoma and Lymphoma
To illustrate the application of these techniques to studies of
human cancer, we will describe studies of human melanoma
models grown in culture, as perfused tumor cells grown on
solid microcarrier beads and as xenografts in immunosuppressed
mice. The cell studies will be utilized to validate the bonded
cumomer model and to estimate the contributions of glycolytic
metabolism and mitochondrial metabolism to ATP production
under hyperglycemic (26mM) and euglycemic (5mM) condi-
tions. Effects of euglycemia and hyperglycemia on glutamine
metabolism, flux through the pentose shunt and FA metabolic
pathways will also be evaluated using both 13C MRS and bonded
cumomer analysis as well as LC–MS and fragmented cumomer
analysis.
To demonstrate how 13CMRS and LC–MS can be used to detect
response to signal-transduction inhibitors, we will present data
on the effect of rapamycin, a well known inhibitor of the mTOR
pathway, on DLCL2 human diffuse large B-cell NHL cells grown
in culture as perfused cells immobilized by encasement in agarose
beads and as xenografts in immunosuppressed mice. We will
FIGURE 2 | The dynamic multiplet control coefficients and sensitivity analysis. (A) In the left panel, the dynamic multiplet control coefficients are shown with
respect to glutaminolysis flux for the glutamate-C4 total and doublet C4d34 and singlet C4s multiplets and the glutamate-C3 and glutamate-C2 total and their
multiplets (right panel) during perfusion with medium containing [1,6-13C2] glucose and unlabeled glutamine. Data show the time courses of normalized multiplet
sensitivities to variation of the glutaminolysis flux. For simulation, the conditions were chosen to optimize extracted fluxes, while glutaminolysis flux was set at 5% of
the TCA cycle flux. The glutamate doublet 4d34 is the most sensitive glutamate multiplet to measure glutaminolysis net flux during the first ~1.5 h, and afterwards the
4s singlet becomes more sensitive. The data in the right panel demonstrate the superior sensitivity of the glutamate 3d doublet at the beginning and glutamate 2s
singlet after ~1.5 h. (B) Total relative mean squared error (MSE) sensitivity function output during perfusion with medium containing [1,6-13C2] glucose and unlabeled
glutamine with respect to free fitted fluxes. Upper panel shows the sensitivities to the TCA cycle, anaplerotic net flux at the level of SucCoA and mitochondrial malic
enzyme activities; and lower panel shows MSE sensitivities to the pyruvate carboxylase (pc), exchange flux α-Kg$glu (x), exchange flux at the level of SucCoA (ana)
and glutaminolysis flux (gls). Note also the significant sensitivities for the fluxes in the upper panel and higher sensitivity for glutaminolysis compared to other fluxes in
the lower panel.
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demonstrate that response to this inhibitor can also be monitored
by 1HMRS lactate imaging in cells and in xenografts. Ultimately,
the goalwill be to translate thesemethods into the clinic tomanage
humanNHLpatients. Preliminary studies leading to this approach
have been published (15).
MATERIALS AND METHODS
Cell Culture
The human DB-1 melanoma cell line was derived by David Berd
from a lymph node metastasis of one of his patients (Thomas Jef-
ferson University Hospital, Philadelphia, PA, USA) before admin-
istration of any treatment. Cells were cultured from the tumor
and cryopreserved after the 16th passage. Monoclonal antibodies
were used to confirm cell surface antigens (61). DB-1 cells were
grown as monolayers for routine culture at 37°C in 5% CO2 in α-
MEMmedium supplemented with 10% fetal bovine serum, 2mM
glutamine, 26mM glucose, and 1% (v/v) non-essential AAs and
10mM HEPES buffer. In tissue culture flasks, the doubling time
was 48 h (50). The V600E BRAF mutation is expressed by the
DB-1 cells.
Cell Perfusion and NMR Spectroscopy
ForNMR studies of perfused tumor cells, DB-1 cells were cultured
in DMEM with 1% non-essential AAs (Invitrogen, Grand Island,
NY, USA), 10% fetal bovine serum, 10mM HEPES, 4mM glu-
tamine, and 26mM glucose (complete DMEM). Approximately
5 108 cells were grown on the surface of non-porousmicrocarri-
ers that had amean diameter of 170microns (Solohill, AnnArbor,
MI, USA). These microcarriers were coated with either collagen
or ProNectinF® to enhance cell attachment and proliferation and
tightly packed inside a 20mm NMR tube in which they were
perfused continuously in the open bioreactor system. Mancuso
et al. (62) have published a detailed description of the perfusion
system, including flow rates, cell adhesion procedures, etc.
The method of Bental et al. (63) was used to immobilize lym-
phoma cells (DLCL2) by encapsulation into agarose beads. In
brief, we thoroughly mixed 1.5ml of ~5 108 cells in culture
medium with an equal volume of the low-temperature-gelling
agarose at 37°C andmagnetically stirred themixture after addition
of 3ml paraffin oil at 37°C generating the cell-encapsulated spher-
ical beads with 100–200μm diameters. The beads were cooled by
continuous stirring, and the oil was removed by centrifugation.
The encapsulated cells were then loaded into a 10mm NMR tube
connected to the perfusion system.
Medium was circulated through the microcarriers or agarose
gel at a flow rate of 12ml/min with a peristaltic pump (Masterflex,
Cole Parmer, Chicago, IL, USA). A gas-exchange module consist-
ing of a siliconemembrane (thin-wall silicone tubing) was situated
before the perfusion chamber along the medium flow path for
removal of carbon dioxide and addition of oxygen. The oxygen
level was measured continuously with a polarographic oxygen
probe (Mettler-Toledo, Columbus, OH, USA) situated at the inlet
port to the perfusion chamber and maintained at a steady-state
pressure near air saturation. The medium was then warmed to
40°C, and a second polarographic oxygen probe was used to
detect the oxygen level of the medium coming out of the NMR
tube permitting the oxygen consumption rate of the culture to be
monitored continuously from the decrease in pO2. A pH probe
(Mettler-Toledo, Columbus, OH, USA) was inserted downstream
of the outlet oxygen probe. Adjustment of the level of CO2 in
the gas-exchange module was used to modify/maintain the pH of
the medium. The temperature of the medium entering the NMR
tube was monitored with a thermocouple at the exit port of the
perfusion chamber andwas fine-tunedwith amicrostat-controller
and an electrical resistance heater to 37.0 0.2°C. The glucose
concentration in the recirculating medium was maintained at a
constant level (clamped) by continuously feeding fresh medium
typically at a flow rate of 24ml/h and removing depleted medium
from a recirculation bottle while maintaining the total volume of
recirculating medium at 120ml. During 13C experiments, 32mM
[1,6-13C2] glucose was fed into the system, and the recirculating
glucose level was clamped at 26mM by adjusting the feed rate.
13C NMR spectra were acquired with standard 1H decou-
pled NOE 13C acquisition on a 9.4 T/89mm vertical bore Varian
spectrometer (Varian Inc., Palo Alto, CA, USA) with acquisition
parameters: 60° pulse angle, 1.2 s repetition rate, 25,000Hz spec-
tral width, 16,384 points, and 750 transients per spectrum. Free-
induction decays were apodized by exponential multiplication
(2Hz) for signal to noise enhancement and peak areas were mea-
suredwithNutsNMR(AcornNMR, Fremont, CA,USA) software.
The number of cells in the NMR tube was determined from the
total NTP level measured by 31P NMR as described previously
(64) using the following spectral parameters: 60° pulse angle, 1 s
repetition rate, 15,000Hz, 1,200 transients.
Melanoma cells were initially studied under normoxic hyper-
glycemic (26mM glucose) conditions to enhance lactic acidosis
(65, 66) and subsequently under normoxic euglycemia (5mM
glucose) to more closely simulate in vivo conditions. The effect
of these changes in glucose concentration on flux through various
pathways of tumor metabolism was determined over a ~6 h time
course during which the kinetics of labeling of lactate, glutamate
and other metabolites was monitored. The estimated TCA cycle
flux was compared to the oxygen consumption flux to test the
accuracy of the calculations.
In vivo animal studies
Immunosuppressed mice were used for in vivo studies. Tumors
were developed by subcutaneous implantation of tumor cells to
the flanks of nude mice. NMR studies on mice were performed
using a home-built 13C/1Hdual-tuned probe at 9.4 T (Varian Inc.).
All animal studies were approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of Pennsylvania,
and performed in accordance with its regulatory standards.
Statistical Analysis
Student’s t-test was used to calculate p-values. P-values <0.05 were
considered significant.
RESULTS AND DISCUSSION
Melanoma Studies
Determination of the relative levels of glycolytic and oxida-
tive metabolism of specific tumors plays an important role in
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development of strategies for treating neoplasms and for choos-
ing appropriate methods to detect tumor response to specific
therapies. Development of a non-invasive method for quantify-
ing the fraction of ATP production by tumors that occurs by
glycolytic and mitochondrial metabolism would be very useful
in the management of cancer patients and tailor-fitting of ther-
apeutic regimens to their individual needs. In addition, various
other pathways of tumor metabolism play critical roles in tumor
proliferation by providing essential precursors for cell replication.
We, therefore, sought to develop a method for quantitating tumor
intermediary metabolism in cells with appropriate extension to
animal tumor models and eventually to human cancer patients.
Metabolic Fate of [1,6-13C2] Glucose in
DB-1 Cells
The entire metabolic network that is included in the current
analysis is depicted in Figure 1. Figures 3A and 4 summarized
13C labeling kinetics of DB-1 melanoma cells grown at a constant
glucose level of 26mM. Dynamic 13C NMR spectra obtained
during the experiment appear in Figure 3A. We detected reso-
nances of C3 lactate, C2, C3, and C4 glutamate, C2 and C3 of
aspartate, and fatty acyl carbons. Under hyperglycemic conditions
(26mM glucose), lactate labeled at C3 (20.9 ppm) appeared in
the spectrum within the first few minutes (Figures 3A and 4C).
Levels of this metabolite increased throughout the experiment
but did not reach saturation. Lactate resonance intensity was the
combined result of the biological rate of lactate formation and the
rates of washout of lactate due to the continuous addition of fresh
medium andwithdrawal of spentmedium from the perfusion sys-
tem. Fifteenminutes after introduction of labeled glucose, isotopic
13C incorporation in C4 of glutamate (34.3 ppm) was detected;
Figure 4A shows the full-time course for labeling results for this
resonance. The concentration of C4-labeled glutamate increased
linearly for ~1 h. Satellites were subsequently detected indicat-
ing the presence of 13C-13C coupling between glutamate-C4 and
glutamate-C3 (1). The rate of labeling of glutamate exclusively on
C4 (producing a singlet peak) gradually slowed and approached
steady state after approximately 6 h. The level of coupled glutamate
labeled at both C3 and C4 continued to increase steadily through-
out the experiment. Labeling of the glutamate-C3 resonance at
28.8 ppm is displayed in Figures 4A,B. 13C labeling of this carbon
increased linearly but did not reach saturation. Approximately,
two-thirds of the C3 glutamate carbon was coupled (predomi-
nantly to glutamate-C4). Within 1 h, glutamate-C2 labeling was
detected (Figures 4A,B). However, only a singlet was observed
for the first 3 h, unlike glutamate-C3 which exhibited multiplet
structure. Subsequently, a doublet appeared due to the presence
of glutamate-C2,3 labeling after carbon 1 was removed from
glutamate-C3,4 during the third turn of the TCA cycle (1).
Labeling was also observed in long chain FAs at approximately
30 ppm, indicating that DB-1 melanoma cells produce lipid de
novo from glucose (see Figure 4D), consistent with results for
other cancer cell lines grown in culture (67). Low levels of labeling
of aspartate-C2 and C3 were also observed. Labeling of alanine
was not detected, probably due to the low total concentration of
this AA; this result is unusual since most cancer cell lines pro-
duce 13C-labeled alanine from glucose (62, 67). Resonances were
observed at approximately 65 ppm, a spectral region associated
with the glycerol backbone of phospholipids in triglycerides as
well as other glycolytic intermediates.
Quantifying Bionetwork Fluxes
We utilized Bonded Cumomer analysis to fit 13C NMR DB-1
melanoma data acquired during continuous perfusion of cells
with [1,6-13C2] glucose in the bioreactor system. Isotopomer
time course data were converted to 13C-metabolite concentration
curves (Figure 4). Only those multiplets with end-point concen-
trations >0.5mM were used in the fitting procedure in order to
minimize the bias introduced by using multiplets with low signal
to noise ratio. Since the noise level of the remaining experimental
multiplets was expected to be high (not shown), these resonances
were used only as reference points for visually examining the fit
predicted for low intensity curves to experimental data but not
FIGURE 3 | Time course 13C NMR spectra of perfused DB-1 melanoma cells in a bioreactor (A), and of a DB-1 melanoma xenograft (B). Glu, glutamate;
Lac, lactate; Glc, glucose; std, ethanol in capillary; FA, –CH2– groups in long chain fatty acids. [1,6-13C2] glucose was used as the substrate for 13C-labeling.
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FIGURE 4 | Time courses for labeling of glutamate, lactate, and fatty acyl resonances during perfusion with medium containing [1,6-13C2] glucose
and unlabeled glutamine. (A) Time course fits for labeling of glutamate (indicated with “fit” ending) at positions 4, 3, and 2. Glu4, 13C at glutamate-C4; Glu4s,
singlet at glutamate-C4; Glu4d34, doublet at glutamate-C4. Glu2, 13C enrichment at glutamate-C2; Glu3, 13C at glutamate-C3. “fit” ending stands for the model fit
and no-ending reflects experimental values. (B) Time courses for labeling glutamate at positions 2 and 3. Fitted curves labeled with ending “fit” are Glu2 and Glu3
total; Glu2s, singlet at glutamate-2; Glu3s, singlet at glutamate-3; Glu3d, doublet at glutamate-3. PE stands for positional enrichment – this is predicted
mitochondrial enrichment of acetyl-CoA at position C2 and mitochondrial Pyr at position C3 multiplied by factor 10. Curves are fit, and points are experimental data.
(C,D) Experimental data and least-squares fit of time course for labeling of lactate-C3 and fatty acyl methylene (–(CH2)n–) resonance in proliferating DB-1 melanoma
cells. (C) Time course for labeling of total lactate-C3 (medium+ intracellular). (D) De novo lipogenesis in melanoma cells. Time course for labeling of fatty acyl
methylene (–(CH2)n–) resonance. [This research was originally published in Journal of Biological Chemistry. Shestov et al. (14). © the American Society for
Biochemistry and Molecular Biology.]
for calculating the goodness of fit of these metabolite resonances.
Four types of measurements were used to quantify tumor central
metabolic fluxes: three sets of time courses of (1) glutamate iso-
topomers (multiplets), (2) total lactate-C3 labeling, (3) acyl groups
of FA resonances determined by NMR in situ, and (4) steady-
state 13C NMR lactate isotopomers. The following time courses
were utilized in the curve-fitting procedure: Glu4Tot (Total: Tot),
Glu4s, Glu4d34, Glu3Tot, Glu3d, Glu2Tot, Glu2s, Lac3Tot, and
acyl methylene (–(CH2)n–) resonance, yielding a total of nine
curves. Estimation of the model-free parameters was achieved
by fitting labeling patterns of glutamate, lactate, and FAs acyl
methylene groups. Table 1 and the flux map in Figure 1 summa-
rized the fluxes determined by the fitting procedure. Monte Carlo
simulations were used to estimate errors in parameters included
in Table 1.
Model Validation
To validate the bonded cumomer network model, we compared
parameters inferred from the model with experimentally deter-
mined values. We measured the O2 consumption rate (MRO2)
with polarographic oxygen probes during the perfusion experi-
ment. The fluxes obtained by fitting of dynamic 13Cdata produced
good agreement between the experimentally observed oxygen
consumption rate, 33mmol/L-cell/h, and the calculated MRO2,
32mmol/L-cell/h (see Tables 2 and 3). The experimental total
glutamate concentration was 8.6mM that was in good agree-
ment with the calculated glutamate pool size of 9.2mM. The
measured glucose consumption rate (MRglc) was 90mmol/L-
cell/h, that compared favorably with the predicted MRglc of
81mmol/L-cell/h. The measured lactate production flux (CMR-
lac) was 155mmol/L-cell/h, whereas the predicted CMRlac was
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TABLE 1 | Extracted fluxes using bonded cumomer modeling.
Reaction Flux
(mmol/L-cell/h)a
Pentose phosphate pathway (oxidative branch), net PPP
FpppOx
3.372%
Transketolase 1 (exchange) relative to glycolysis, TK1 2156%
Transketolase 2 (exchange) relative to glycolysis, TK2 0.590%
Transaldolase (exchange) relative to glycolysis, TA 4464%
Glucogenic amino acids contribution to pyruvate, Fgaa 5.020%
TCA cycle rate, Ftca (isocitrate! α-Kg) 10.98%
Exchange, Mal-Asp shuttle, Fx (reversible) 11.319%
Pyruvate carboxylase Flux, Fpc 0.651%
Anaplerotic exchange flux at SucCoA, Fxana 3.015%
Net Anaplerotic flux to the TCA cycle, dFana 4.315%
Flux of ketogenic AA and FA to Acetyl-CoA formation, Fkaa 0.119%
Glutaminolysis Flux, Fgls 0.0560%
Pyruvate dehydrogenase Flux, Fpdh 10.816%
Citrate synthase flux, Fcs 11.514%
Net fumarase activity, Fum!Mal, Ffum 15.316%
Fatty acids synthesis, Ffas 0.5915%
Mitochondrial pyruvate transport, Fmpc 7.123%
Malic enzyme (mitochondrion), ME2+ME3, Fmem 4.312%
Malic enzyme (cytosolic), ME1, Fmec 0.615%
Aspartate efflux, dFxasp 0.0645%
Production Flux of ATP, glycolytic, Warburg, FatpCyt 15013%
Production Flux of ATP, mitochondrial, oxphos, FatpOx 15412%
Warburg parameter (net LDH/MPC flux ratio) 2124% (unitless)
Combined glycolysis and PPP flux from G6P to pyruvate 152.112%
Glutamine consumption flux (for protein, nucleotides, amino
acids, glutathione, etc)
4.910%b
Net LDH activity, Pyr! Lac, Fldh 15012%
Lactate transport, Vmaxlac 39512%
Lactate transport, Michaelis–Menten parameter, Km 3.5mM70%
aCalculated rates of flux are expressed in millimoles per liter-cell per hour with relative SDs
in percent for pathways shown in Figure 1. Warburg parameter is the ratio of the net flux
through lactate dehydrogenase (LDH) to the mitochondrial pyruvate carrier influx (MPC).
bSD was estimated based on experimental measurements of glutamine consumption.
This research was originally published in Journal of Biological Chemistry. Shestov et al.
(14). © the American Society for Biochemistry and Molecular Biology.
150mmol/L-cell/h. We note that we did not use experimen-
tally measured fluxes as constraints in our Bonded Cumomer
metabolic flux analysis.
Tables 2 and 3 also compare glucose and glutamine uptake
under euglycemic (6mM glucose) and hyperglycemic (23mM)
conditions. Under euglycemic conditions, glutamine influx
approximately doubles, whereas glucose consumption remains
essentially unchanged.
Finally, we were able to generate a flux map that was included
with the bionetwork in Figure 1. This figure shows the extracted
metabolic fluxes with the predicted oxygen consumption rate
MRO2. Numbers indicate fluxes in mmol/L-cell/h. See Table 1
for definitions and values of the derived fluxes; Table 2 summa-
rizes the predicted and calculated metabolic rates derived from
TABLE 2 | Experimental data compared to calculated values determined by
dynamic bonded cumomer modeling (mmol/L-cell/h).
Reaction Exp. Flux
(mmol/L-cell/h)
Calculated flux
(mmol/L-cell/h)
Oxygen consumption MRO2 36 32
Glucose uptake 91.0 85
Pyruvate to lactate 155.0 150
Glutamine uptake 5.0 –a
Glutamate concentration 8.6mM 9.2mM
aThe flux was not estimated, as glutamine is consumed in numerous reactions we did
not study here. This research was originally published in Journal of Biological Chemistry.
Shestov et al. (14). The American Society for Biochemistry and Molecular Biology.
TABLE 3 | Experimental glucose and glutamine consumption fluxes under
euglycemia (6.4mM) and hyperglycemic conditions (23.2mM in medium).
Glutamine flux Glucose flux
Euglycemia (6.4mM) 0.064 0.86
Hyperglycemia (23.2mM) 0.035 0.79
Glutamine [Gln]= 3.0mM at low glucose and 3.4mM at high glucose. Fglc, glucose
consumption flux (mmol/109cells/h) and Fgln, glutamine consumption (mmol/109cells/h).
Flux ratios were Fglc/Fgln= 22.4 at high glucose and Fglc/Fgln=13.5 at euglycemia.
This research was originally published in Journal of Biological Chemistry. Shestov et al.
(14). © The American Society for Biochemistry and Molecular Biology.
these data. The excellent agreement betweenmodel-predicted and
experimental values validates the model.
Quantifying ATP Production Routes
The predicted fluxes were used to calculate contributions of gly-
colysis and oxidative phosphorylation (oxphos) to ATP produc-
tion. We assumed that the oxidative phosphorylation P/O ratio
equals 1.5 for FADH2 and 2.5 for NADH oxidation. To assess the
contribution of glucose, FAs and glucogenic AAs and glutamine
to generating reducing power, we calculated the fluxes for each of
these metabolites. For each of the above substrates, we calculated
the NADH/FADH2 reaction flux based on the different labeling
patterns that we were able to track both from the labeled and
unlabeled C atoms. The combined cytosolic ATP production flux
was 150mmol/L-cell/h, and themitochondrial compartment pro-
duced 154mmol/L-cell/h due to oxidative phosphorylation. The
results are presented in Table 1.
Consequently, about 50% of the energy of this tumor model
comes from oxidative metabolism, whereas many authors have
suggested that tumors derive most of their energy from aerobic
glycolysis. The glycolytic contribution will, no doubt, increase
in vivo where tumors are often located in regions of hypoxia,
which produce a Pasteur effect, and, hence, a shift toward
glycolytic metabolism; however, it is likely that many tumors like
melanomas will be strongly dependent on oxidative metabolism
for their energy source, particularly in tumors that express the
V600E BRAF mutation, about 50% of human melanomas. (68)
High fluxes of pyruvate mitochondrial transport (~70% of the
TCA cycle activity) and mitochondrial ATP production are
promoted by melanoma associated BRAF mutation. Recent work
(69) has demonstrated that BRAF V600E mutated melanoma
cells exhibit increased pyruvate entry through the activated
PDH. PDH flux (~106% of the TCA flux) is regulated by
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phosphorylation/dephosphorylation mediated by PDH kinase
(PDK) and PDH phosphatase (PDP). The oncogene BRAFV600E
causes concerted activation of PDH complex by downregulation
of PDK1 expression and upregulation of PDP2 thereby promoting
oxidative pyruvate utilization and leading to increased cellular
respiration.
Pentose Phosphate Pathway
Weused the Bonded Cumomer fluxmodel to fit 13CNMR steady-
state data acquired after 8 h incubation of DB-1 cells with [1,2-
13C2]glucose tracer. The fitted steady-state data were Lac3Tot,
Lac2Tot, Lac3s, Lac3d23, Lac2s, and Lac2d23 multiplets. All the
experimental 13CNMR spectra and the results of fitting are shown
in the Figure 5. The extracted fluxes relative to glycolytic flux are
presented in Table 1. Flux SDs were calculated by Monte Carlo
calculations. Flux through the oxidative PPP was estimated to
be 3.6% of the glycolytic rate. Given the extensive experimental
data that have been obtained for the lactate 13C NMR multiplets,
we were also able to estimate non-oxidative exchange fluxes (the
smallest rate for reversible reaction) of the classical PPP (Figure 1),
which are presented in Table 1. Transketolase 1 and transaldolase
exchange fluxes in the non-Ox PPP branch were consequently
relatively high at 21 and 44%, respectively, and transketolase 2
activity was close to 0. The flux SDs (Table 1) demonstrate that all
fluxes through PPP were resolved with relatively poor resolution
when using only 13C NMR isotopomers of lactate as a reporter
molecule. NADPH production flux via the oxidative PPP pathway
was estimated to be 6.6mmol/L-cell/h.
Quantifying Glutaminolysis Flux
Our recent focus has turned to refinement of the details of glu-
taminolysis because of its critical role in the metabolism of many
malignancies. For example, one glutamine molecule could pro-
duce up to 22.5 ATP molecules. Therefore, even a small amount
of glutaminolysis can have a major effect on the bioenergetics of
cancer cells. In DB-1 melanoma under hyperglycemic conditions,
glutamine uptake flux ranged up to 50% of the TCA cycle flux.
Under euglycemic conditions, glutamine uptake doubled reaching
approximately the same level as TCA cycle flux. Glutamine uptake
can lead to protein synthesis, glutathione synthesis, or nucleotide
synthesis as well as to ATP production by the glutaminolysis
pathway (see below) or to cytosolic reductive carboxylation (RC)
driven by glutaminase 1 (GLS; it is considered to be present
both in mitochondria and cytosol) or other glutamine–glutamate
conversion enzymes in cytosol and isocitrate dehydrogenase 1
(IDH1) (70). It was, therefore, important to refine the metabolic
analysis of DB-1 melanoma to accurately assess the contributions
of the glutaminolysis pathway in these tumor cells (See Figure 1).
In order to quantify the glutaminolysis contribution to energy
production, we modified the bionetwork simultaneously allowing
net glutamine influx into mitochondria through glutaminase 1
and 2 (GLS and GLS2) (Figure 1).
“Classical” glutaminolysis includes uptake of glutamine by
the cell, transport to mitochondria, conversion to glutamate
through mitochondrial glutaminase 1 or 2 (GLS and GLS2), and
finally entry into the TCA cycle to α-ketoglutarate via GLUD1
and GLUD2 or via mitochondrial aminotransferases (GPT2 and
FIGURE 5 | High-resolution 13C and 1H NMR spectra of lactate from
DB-1 cells incubated with [1,2-13C2] glucose and experimental lactate
multiplets vs. fit. (A) 13C NMR spectra. The left panel shows the NMR
spectrum at the chemical shifts around lactate C2, and the right panel shows
the spectrum around lactate C3. 2s, lactate singlet at C2 position; 2d32,
lactate C2 doublet with carbon coupling between the carbon 2 and 3
positions; 3s, lactate singlet from the C3 position; 3d23, lactate C3 doublet
with carbon coupling between the carbon 2 and 3 positions. (B) Proton-
observed carbon-edited (POCE) 1H NMR spectra. The upper panel shows the
labeled lactate and the lower panel shows the unlabeled lactate. (C)
Experimental multiplet fraction (left bars, black) vs. fitting (right bars, patterned)
for lactate C3 and C2, and the predicted lactate C1 multiplets, based on the
evaluated oxidative and non-oxidative branches of the PPP. Error bars
indicate SDs. The extracted oxidative PPP flux and the relative exchange
fluxes for transketolases and aldolase are presented in Table 1. [This research
was originally published in Journal of Biological Chemistry. Shestov et al. (14).
© the American Society for Biochemistry and Molecular Biology.]
GOT2). Alternatively, glutaminolysis could partially occur in the
cytosol by producing glutamate or α-ketoglutarate from glu-
tamine and eventually by entry of those metabolites in to the
TCA cycle via α-ketoglutarate. Further flux in the TCA cycle then
moves tomalatewheremalate–pyruvate cycling occurs (Figure 1).
There are two pathways for pyruvate-malate cycling. One pathway
involves conversion of malate via mitochondrial malic enzyme
(ME2) to pyruvate; it then returns to oxaloacetate via PC, or it
can go from pyruvate to acetyl-CoA leading to citrate. The second
pyruvate cycling pathway goes from malate in the mitochondria
through a transporter into the cytosol and from there to cytosolic
pyruvate via cytosolic malic enzyme (ME1). The cytosolic pyru-
vate can return to the mitochondria through the MPC or it can
be converted to lactate via LDH or to alanine via alanine amino-
transferase (GPT1). The BC approach can distinguish between
these pyruvate–malate pathways or their combinations under real
conditions (Figure 1).
We continue the analysis of data ofDB-1melanoma cells treated
with [1,6-13C2]glucose as the tracer with respect to sensitivi-
ties of the experimental multiplets to glutaminolysis. Dynamic
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isotopomer control analysis (ICA) indicates that the curves result-
ing from fitting of the C4-labeled glutamate multiplets, particu-
larly the glutamate 3,4 doublet-glu4d34 resulting from simultane-
ous labeling of C3 and C4 (during the second TCA cycle turn)
and the singlet resulting from glutamate labeling exclusively at
C4 (during the first turn of the TCA cycle) are very sensitive to
flux through the glutaminolysis pathway even when only natural
abundance medium glutamine has been used. See for example
Figure 2A, where we display the dynamic multiplet control coef-
ficients with respect to glutaminolysis activity for the glutamate
C4 total and the glutamate C4 singlet and 3,4 doublet-4d34, and
for the glutamate C3 and C3d doublet and glutamate-C2 and C2s
singlet. This figure clearly indicates that glutamate labeling kinet-
ics is sufficiently sensitive to glutaminolysis flux and that there
is no need to purchase or synthesize exotically labeled glutamine
(with 13C, 15N, or 2H labeling) to evaluate glutaminolysis. Control
simulation was based on the optimal set of extracted fluxes, and
glutaminolysis fluxwas set at 5%of theTCAcycle flux. The plotted
dynamic glutamate multiplet control coefficients indicate that the
glutamate doublet 4d34 is the most sensitive glutamate multiplet
with respect to glutaminolysis net flux during the first ~1.5 h
when the sensitivity of the RGlu4d34 doublet is positive (positive
mode) and afterwards when the RGlu4s singlet 4s becomes most
sensitive in the negative operation mode. The data in the right
panel ofFigure 2Ademonstrate the superiority of the sensitivity to
glutaminolysis flux of the glutamate 3d doubled at the beginning
and glutamate 2s singlet during the time course after ~1.5 h.
We then evaluated the contribution of glutaminolysis flux to
overall energy production of DB-1 melanoma cells. We found
that for this tumor line, glutaminolysis flux through the truncated
TCA cycle and via pyruvate–malate cycling by malic enzyme
ME2 is essentially 0. This conclusion resulted directly from the
ability of the model to detect glutaminolysis flux by fitting of data
on the glutamate multiplets (see above). To further confirm this
conclusion, we forced the model to accommodate glutaminolysis
flux between 5 and 20% of the TCA cycle flux. Invariably, this
grossly deteriorated the goodness-of-fit of the isotope kinetic data
to the model (results not shown).
Even though glutaminolysis does not contribute substantially
to mitochondrial ATP production, there is still substantial mito-
chondrial malic enzyme flux (combined activities of NADH pro-
ducing ME2 and NADPH producing ME3), which is equal to
approximately 40% of the TCA flux (see Table 1).
There has been considerable interest in glutamine metabolism
as a key source of tumor energy production linked to c-myc
expression (71–75). Our model of tumor metabolism (Figure 1)
contains a specific glutamine transporter on the cell membrane.
The classical model of glutaminolysis includes an additional
specific glutamine transporter on the mitochondrial membrane
that leads to mitochondrial glutaminase (GLS2 or GLS), which
converts glutamine to glutamate, which is then converted to α-
ketoglutarate by enzymes, such as GLUD1 and GLUD2. Two
additional transaminases can carry out the glutamate to α-
ketoglutarate exchange, aspartate aminotransferase, and alanine
aminotransferase. The α-ketoglutarate then produces reducing
equivalents via the oxidative branch of the TCA cycle leading
to ATP production by oxidative phosphorylation. Various path-
ways, including the malate-aspartate shuttle, PC, malic enzyme,
and phosphoenolpyruvate carboxykinase (PEPCK1 and 2) all
contribute to metabolism of the glutamine carbon atoms. As
previously noted, glutamine metabolism can lead to production
of 22.5 molecules of ATP per glutamine molecule. In the case of
DB-1 melanoma cells under hyperglycemic conditions, glutamine
influx constituted about 50% of the TCA cycle flux, with about
double this level of glutamine uptake under euglycemic condi-
tions (Tables 2 and 3). However, the transaminase reactions are
reversible andmay exhibit high exchange fluxes in both directions
with very little net glutamine uptake by the TCA cycle and nearly
no energy production from the glutaminolysis pathway in DB-1
cells. It is important to note that because carbon atoms of gluta-
mate originating from glucose will be isotopically labeled (first on
C4 position and then onC2 andC3, etc.), whereas carbons coming
fromglutaminewill be unlabeled, it was possible to distinguish the
two pools of carbon atoms originating from these two substrates.
The data fitting clearly indicated that the net flux from glutamine
being metabolized via the TCA cycle was very small.
We also conducted a sensitivity analysis to show that using
[1,6-13C2] glucose tracer alone is enough to reliably calculate glu-
taminolysis flux in malignant cells and tissues. Figure 2A shows
that the glutamate-C4 doublets due to C3–C4 coupling (glu4d34)
is most sensitive to glutaminolysis and all experimental glutamate
multiplets, including total positional enrichments at glutamate
C4, C3, and C2 are sensitive to the net flux of unlabeled glutamine
entering the TCA cycle. Fitting analysis indicated that there was
little net influx from glutamine into the TCA cycle. Note also that
this conclusion can also be reached from 13C NMR data without
the use of labeled glutamine.
By contrast, some investigators utilizing mass spectrometry
have equated glutamine uptake minus glutamate release with net
glutaminolysis flux (76). In the present case, the net influx of
glutamine is ~5mmol/L-cell/h, which, if it were equated with
glutaminolysis flux, would have been interpreted as 113mmol/L-
cell/h of ATP per h or about 75% of the glycolytic produc-
tion of ATP. Under euglycemic conditions, which produce about
twice the level of glutamine uptake, such an analysis would have
attributed about 50% higher ATP production to glutaminolysis
rather than to glycolysis, andmost of the tumor energy production
would have been attributed to glutaminolysis. This is incorrect
in our case; in reality the net glutaminolysis flux under hyper-
glycemic conditions is ~0.1mmol/L-cell/h or ~2mmol ATP/L-
cell/h or ~1% of the glycolytic ATP production rate. Bonded
Cumomer analysis provides a method for making this crucial
distinction. Our labeled LC-MS data for the TCA cycle inter-
mediates with [U-13C5, U-15N2] glutamine confirmed that no
glutaminolysis occurred under euglycemic conditions vs. hyper-
glycemia (Figure 6). The absence of change in glutaminolysis
or RC flux is evident from similar mass-isotopomer distribution
(MID) of several key metabolites. Our finding of nearly zero glu-
taminolysis flux contradicts the view of Scott et al. (77), who, on
the basis of glutamine uptake and label appearance in some TCA
cycle metabolites, concluded that glutamine was utilized as an
anaplerotic substrate of several human melanoma lines. However,
these authors failed to conduct a rigorous metabolic modeling
analysis to measure flux through the TCA cycle. Consequently,
they were unable to distinguish between actual flux through
the cycle via glutaminolysis and exchange labeling between
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FIGURE 6 |Mass-isotopomer distribution (MID) for the TCA cycle
intermediate and acetyl-CoA measured at hyperglycemic and
euglycemic conditions during [U-13C5] glutamine labeling. MID of (A)
citrate, (B) malate, (C) succinate, and (D) acetyl-CoA. The figure clearly
demonstrates that there are no significant differences in labeling patterns of
key metabolites (p-value was always >0.05) between 5mM glucose and
25mM medium glucose conditions. [This research was originally published in
Journal of Biological Chemistry. Shestov et al. (14). © the American Society
for Biochemistry and Molecular Biology.]
α-ketoglutarate and glutamate without any net flux. In addition,
glutamine could be used for many other metabolic processes
besides energy production, e.g., protein and nucleotide synthesis.
If the net uptake of glutamine is 5mmol/L-cell/h with negligible
contribution to energy production, glutamine must be contribut-
ing primarily to anabolic processes, such as AA, nucleotide, and
protein production as well as to de novo lipogenesis.
Effect of Hyperglycemia/Euglycemia on
Glutamine and Fatty Acid Metabolism
The MID of several TCA cycle metabolites from [U-13C5, 15N2]
glutamine labeling experiments is shown in Figure 6 at different
glucose concentrations in the medium – at 5mM for euglycemia
and 25mM for hyperglycemia. With this tracer, increased glu-
taminolysis flux resulted in increased abundance of M+ 4 mass-
isotopomer of citrate, succinate, and malate (70), whereas RC
resulted in increased M+ 3 for malate, M+ 4 for succinate, and
M+ 5 for citrate. RC and increased glucose contribution to the
FAs production also disturbs the acetyl-CoAmass-MID. Figure 6
clearly shows that there are no significant differences in labeling
patterns of all fourmetabolites. Consequently, based on bioreactor
data, we can exclude any major change in glutaminolysis flux as
well for FA production during hyperglycemia vs. euglycemia.
Quantifying De Novo Lipogenesis
Flux in DB-1 Cells
During culturing of DB-1 cells with [1,6-13C2] glucose, pro-
gressive labeling of FAs was observed for multiple resonances
(see Figures 3 and 4D). FA synthesis occurs first by cytosolic
citrate production from glucose and through RC in cytosol from
glutamine through isocitrate dehydrogenase (IDH1 isoform). By
ATP citrate lyase, cytosolic citrate is converted to oxaloacetate
and cytosolic acetyl-CoA, which is converted further to malonyl-
CoA by the rate-limiting acetyl-CoA carboxylase beta (ACC-beta)
and through FAs synthases to elongated precursors via sequential
addition of acetyl-CoA, eventually leading to palmitate produc-
tion. Palmitate is further elongated or desaturated to produce
numerous other FAs. To address de novo FA flux production, we
utilized the BC model with cytosolic FAs and their precursors as
well as membrane FAs as the second FA pool. We calculated FA
concentrations based on the total FA content of approximately
20% of cell dry weight of 200mg/109 cells (5 108 cells= 1ml).
Total FA content referenced to palmitate is at the level of several
tens of mmol/L-cell. We iteratively varied the ratio of cytosolic to
membrane FA and found the best fit at approximately 10 times
more FA in the cytosolic membrane compartment (Figure 4D).
The de novo flux of conversion of glucose to FA was 0.59mmol/L-
cell/h and NADPH consumption flux in FA biosynthesis was
8.4mmol/L-cell/h.
While glutamine-derived carbons have been unlabeled, we have
monitored lipogenesis by 13C NMR detecting methylene carbon
acyl groups originating from labeled glucose (Figures 3A and
4D). Table 1 indicates that de novo lipogenesis corresponds to
~6% of the TCA cycle flux under hyperglycemic conditions.
However, this does not include possible direct contributions
from unlabeled glutamine (i.e., through cytosolic RC by isoci-
trate dehydrogenase IDH1 or mitochondrial IDH2) and poten-
tially from cytosolic acetyl-CoA synthetase 2 (ACSS2) reaction,
which involve participation of cytosolic acetate or acetate from the
medium (78).
This modest flux for de novo FA synthesis requires a large con-
tribution of NADPH cofactor production (~8.3mmol/L-cell/h).
NADPH could be produced by the oxidative branch of the
PPP, ME, or IDH activities or by serine–glycine one-carbon
metabolism (folate metabolism). Our calculated malic enzyme
activities inmitochondria (even if all this activity is represented by
ME3) would account for 4.3mmol/L-cell/h and cytosolic NADPH
flux (ME1, 0.6mmol/L-cell/h) would not account for the required
high level of NADPH flux. A recent elegant study (79) suggested
that in some cancers folate metabolism is the biggest producer
of NADPH. Based on these data (48), we estimated that the
serine–glycine one-carbon SGOC pathway cannot account for the
required NADPH consumption. In light of our 13C NMR lactate
labeling data, the oxidative branch of the PPP is the main pro-
ducer of NADPH in these cancer cells (6.6mmol/L-cell/h). This
constitutes ~80% in agreement with the NADPH consumption
rate during FAs biosynthesis. Thus, the flux through the oxidative
PPP appears to be ~80% sufficient to supply all of the NADPH
required for FA production and is the main supplier of reducing
equivalents in DB-1 melanoma. A 20% difference in the rates of
NADPH production and consumption indicates that alternative
sources of NADP reduction, considered above, need to be taken
into account. We also found that mitochondrial-pyruvate–malate
cycling was very high (4.3mmol/L-cell/h). This could also con-
tribute to defense against reactive oxygen species by producing
sufficient NADPH via ME3.
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Lymphoma Studies
Rapamycin Inhibits mTORC1 Signaling and Lowers
Lactate Concentration in B-Cell Lymphoma Cells
The effects of rapamycin on mTORC1 signaling and cell
growth were first examined in four B-cell lymphoma cell lines,
sub-classified either as germinal-center type DLBCL (DLCL2,
Val, and Ly18) or Burkitt (Ramos). As indicated by loss
of mTORC1-dependent S6rp phosphorylation, rapamycin sup-
pressed mTORC1 activity in all the cell lines and profoundly
inhibited BrdU uptake-detected cell proliferation (15).
We have evaluated the effect of rapamycin on the cellular con-
centration of lactate in NHL cells by 1H MRS (Figures 7A,B)
because mTOR has been implicated in various aspects of cell
metabolism. To varying extents rapamycin significantly decreased
intracellular lactate relative to controls in all four cell lines (15).
Significantly, the relative reduction in intracellular lactate con-
centrations in rapamycin treated cells vs. controls was more pro-
nounced after 48 than 24 h exposure to rapamycin and correlated
with the suppression of cell growth indicating that the effect is
not directly due to drug–enzyme interaction or direct effects on
mTOR signaling but is most likely due to gene translation.
Kinetics of the Rapamycin-Induced Suppression
of Lactate Concentration
To determine how early the rapamycin-induced metabolic
changes can be detected, we examined the intracellular lactate
concentration at 2, 4, 8, 24, and 48 h in two B-cell lymphoma
cell lines (15). While 2 and 4 h exposure to rapamycin did not
have a definitive effect, we noted statistically significant differ-
ences between vehicle- and rapamycin-treated cells at 8 h in both
cell lines (p= 0.002 and 0.03 for DLCL2 and Ramos, respec-
tively; n= 3) with increased differences at 24 and 48 h. Changes
of lactate and glucose concentrations in the medium indicated
diminished glycolysis following rapamycin treatment with cor-
responding changes in lactate secretion and glucose uptake per
cell. Lactate secretion and glucose uptake exhibited maximum
differences between vehicle- and rapamycin-treated cell cultures
at 24 h in contrast to intracellular lactate that remained approx-
imately unchanged. The amount of secreted lactate per cell was
three to four orders of magnitude greater than the intracellular
lactate levels, which indicates that most of the lactate generated by
cellularmetabolismwas secreted by the cell. Nonetheless, the level
of intracellular lactate was more sensitive than secreted lactate
levels for distinguishing metabolic differences between vehicle-
and rapamycin-treated cells. This was, in part, due to the intra-
cellular lactate concentration remaining essentially constant after
rapamycin treatment.
Rapamycin Inhibits Expression of Hexokinase II
While inhibition of mTORC1 signaling by rapamycin reaches an
optimum within minutes after drug administration (80–82), the
drug’s effects on the lactate concentrationwere not detectable until
8 h post-treatment and became more pronounced at 24 and 48 h
in cultured cells (15). This marked timing difference indicates
that the inhibition of glycolysis does not directly result from
inhibition of the mTORC1 signaling but most likely originates
from diminished expression of enzymes involved in the glycolytic
pathway. To test this assumption, we performed gene expres-
sion profiling of the DLCL2 and Ramos cell lines treated with
rapamycin or medium alone (Figure 7C). The component of the
FIGURE 7 | Rapamycin-induced mTOR inhibition and changes in intracellular lactate levels and glycolytic gene expression profiles. (A) 1H MRS
spectra of DLCL2 cells at 24 h (control vs. rapamycin-treated); lactate (1.3 ppm) and the reference TSP peaks (0 ppm, indicated as STD). (B) Intracellular lactate
concentration (mole/cell) for the four listed B-cell lymphoma cell lines treated with 200 nM rapamycin or medium alone for 24 and 48 h (n= 3 for each condition). (C)
Expression of the glycolysis-related genes in the depicted cell lines treated for 6 h with rapamycin or medium alone. (D) Kinetics of the rapamycin-induced changes in
hexokinase II protein expression. Inhibition of S6rp phosphorylation, an indicator of mTOR signaling, is also shown. [This research was originally published in NMR in
Biomedicine. Lee et al. (15). © John Wiley & Sons Inc.]
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glycolytic pathway whose gene expression was most profoundly
inhibited by the rapamycin treatment was hexokinase II although
some other glycolytic genes showed similar trends. The steady loss
of hexokinase II expression was confirmed on the protein level in
all the cell lines examined (Figure 7D).
Rapamycin-Induced Suppression of Lactate
Concentration Directly Correlates with Inhibition of
Lymphoma Growth In vivo
Todetermine if the rapamycin-induced suppression of lactate con-
centration can also be detected in vivo, we evaluated xenotrans-
planted lymphoma models (Figure 8), the DLCL2 and Ramos
B-cell lines studied in greatest detail in vitro as described above.
The tumors displayed the appropriate transformed lymphoid cell
morphology and human B-cell phenotype confirming that they
originated from the implanted lymphoma cell lines.
Administration of rapamycin to mice with DLCL2 and Ramos
xenografts inhibited mTORC1 signaling and decreased the pro-
liferative rate of the lymphoma cells as determined by suppres-
sion of S6rp phosphorylation and decreased expression of the
cell cycle-associated marker mib1 (15). Western blots confirmed
effective and specific mTORC1 inhibition, which revealed greatly
diminished S6rp phosphorylation and intact phosphorylation
of Akt. Prolonged treatment with rapamycin resulted in tumor
growth arrest for the DLCL2 cell line and a marked decrease in
tumor volume for the Ramos cell line (Figure 8). It is noteworthy
that these effects were preceded by decreases in tumor lactate con-
centrations measured by in vivo MRS. The decrease was already
statistically significant at 48 h following initiation of rapamycin
treatment and increased at 96 h. At 2 days after initiation of treat-
ment, the effect of rapamycin on tumor volumewas not yet notice-
ablewhile tumor lactate had already significantly decreased. These
observations strongly suggest that in vivomeasurement of lactate
originating from the tumor provides an early marker predictive of
effective mTOR inhibition that correlates with substantially later
tumor shrinkage.
Discussion of Rapamycin Data
The above results clearly document that mTOR inhibition can be
monitored in vitro and in vivo by measuring changes in lactate
FIGURE 8 | Rapamycin-induced inhibition of tumor growth and glucose metabolism in vivo. Xenotransplants of DLCL2 cells (left panel) and Ramos cells
(right panel). (A) Tumor growth curve. The data are presented as meanSD (n5 in each group). (B) Time course in vivo localized MRS. (C) Lac/H2O ratios
normalized to the pretreatment values; meanSE (n=5). Statistically significant changes in Lac/H2O were observed at 48 h and after from initiation of rapamycin
treatment in both xenografts while control tumors (n= 5) did not have significant changes in Lac/H2O until 96 h. [This research was originally published in NMR in
Biomedicine. Lee et al. (15). © John Wiley & Sons Inc.]
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concentration. Accumulating evidence indicates that mTORC1
can be activated by a variety of cell–surface receptor complexes.
While the original studies implicated the activation of recep-
tors for the insulin-family growth factors (83–85), subsequent
observations by the Wasik laboratory (80–82) and by others (86–
91) demonstrated that a large spectrum of receptors and their
ligands triggered mTORC1 activation. These include interleukin-
2, anaplastic lymphoma kinase, CD40 ligand, notch, thyroid-
stimulating hormone, fibroblast growth factor-9, polycystein-1,
and prostaglandin F2a. These diverse ligand–receptor complexes
activate mTORC1 through the signaling pathways PI3K/Akt (92–
94), MEK/ERK (95), and possibly Syk (96). Therefore, the inhi-
bition of these pathways should also be amenable to detection
by monitoring changes in glycolysis. Given that these pathways
are frequently deregulated in malignant cells and clinical-grade
inhibitors are already available, evaluation of glucose metabolism
as a surrogate for monitoring mTOR activity may prove useful
in the management of cancer patients treated with a variety of
kinase inhibitors. Indeed, inhibition of the oncogenic BCR/ABL
tyrosine kinase led to decreased glucose uptake and lactate pro-
duction (97, 98), all but certainly indicating that mTORC1 signal-
ing was involved (99). Hence, the apparent lack of specificity of
lactate actually reflects its versatility. Provided that a single kinase
inhibitor is administered, there is no lack in specificity of detecting
response to the drug; if multiple kinase inhibitors are used, then
lactate still serves as a biomarker for the combination.
Genomic Analysis of mTOR Inhibition
In view of a recent report (100) that several metabolic pathways
were modified in mouse fibroblasts with hyper-activated mTOR,
we analyzed changes in expression of metabolic genes in DLCL2
and Ramos cells induced by rapamycin. Table 4 lists significantly
affected (up- and downregulated; p< 0.02, n= 3) of representa-
tive metabolic genes in DLCL2 cells (Ramos data are similar).
The anticipated related alterations in the cellular metabolism
indicate that in the DLCL2 cells mTOR inhibition diminishes
not only glucose metabolism but also TCA cycle activity, de
novo FA and sterol biosynthesis, pyruvate cycling activity, and
flux through pentose phosphate pathway. Glutaminolysis should
also be affected due to novel PPAT gene expression, which is
responsible for enzymatic glutamate production from glutamine
(see footnote “b” in Table 4).
Cell Perfusion and 13C NMR Spectroscopy
Figure 9A shows data obtained from DLCL2 cells immobilized
in agarose beads and perfused with normoxic (20% O2, 75% N2,
5% CO2) media containing 5mM [1,6-13C2] glucose over a 12-h
period in a 10mm diameter NMR bioreactor. Cells were studied
before treatment and 24 and 48 h (not shown) after treatment with
rapamycin. Using a two-compartmental enzyme kinetic model,
we calculated lactate production rates. The results were 6.9mM/h
(pretreatment) and 1.6mM/h (post-treatment), which indicate a
profounddecrease in glycolysis. There is also a decrease in labeling
of Glu C4 reflecting a decrease in TCA cycle flux. Alanine and
fatty acid labeling are also diminished, and glycogen stores have
been completely depleted, probably as a result of decreased energy
production by both glycolytic and TCA cycle pathways.
In vivo 13C NMR Studies of DLCL2 Cell Metabolism
Figure 9B shows the time course of 13C MR spectra measured
after infusion of [1,6-13C2] glucose into a mouse with a 12mm
DLCL2 xenograft (500mm3) growing on its flank. The inset to
this figure shows the MR image of the tumor and the Hadamard
voxel that localizes the spectral data in the tumor (i.e., insuring no
contributions from external tissues). These studies demonstrate
the feasibility of performing 13C MRS studies non-invasively in
these in vivo lymphoma tumor models in mice. The spectra show
the time course of labeling of tumor metabolites by transfer of
13C by metabolism of the labeled glucose over 120min with each
spectrum measured in 15min. The same animal was studied
before and 4 days later after seven doses of rapamycin (10mg/kg)
with two doses administered per day (bottom of Figure 9B).
TABLE 4 | Changes in gene expression following treatment of DLCL2 cells with rapamycin.a
Entrez ID Gene Symbol Enzyme name EC number Fold change P value Pathway Affected
Upregulated
5106 PCK2 Phosphoenolpyruvate carboxykinase 2 (mit) EC 4.1.1.32 1.51 0.000434 Pyruvate cycling
Downregulated
3099 HK2 Hexokinase 2 EC 2.7.1.1  1.78 0.00515 Glycolysis
57546 PDP2 Pyruvate DH phosphatase subunit 2 EC3.1.3.43  1.54 0.0150 PDH, TCA
3419 IDH3A Isocitrate DH 3 (NAD+) alpha (mito) EC1.1.1.41  1.60 0.000673 TCA Cycle
5471 PPAT Amidophosphoribosyl transferase EC2.4.2.14  1.73 0.0163 Glutaminolysisb
31 ACACA Acetyl-CoA carboxylase alpha EC6.3.4.14  1.80 0.00518 Fatty acids
2180 ACSL1 Acyl-CoA synthetase long-chain member 1 EC 6.2.1.3  1.52 0.0161 Fatty acids
23171 GPD1L Glycerol-3-phosphate dehydrogenase 1-like EC 1.1.1.8  1.56 0.00446 Glycerophospholipid
22934 RPIA Ribose 5-phosphate isomerase A EC 5.3.1.6  1.58 0.00451 Pentose phosphate
1717 DHCR7 7-dehydrocholesterol reductase EC1.3.1.21  1.72 0.00363 Cholesterol
6307 MSMO1 Methylsterol monooxygenase 1 EC1.14.13.72  1.74 0.0165 Cholesterol
1723 DHODH Dihydroorotate dehydrogenase EC 1.3.5.2  1.51 0.000190 Pyrimidine metabolism
5198 PFAS Phosphoribosylformylglycinamidine synthase EC 6.3.5.3  1.51 0.00120 Purine metabolism
aData were compiled from KEGG database. Gene expression of a large number of enzymes demonstrated statistically significant changes, but only one or two representative enzymes
are listed for pathways showing changes greater than 50%.
bThis is a new link for glutamine to glutamate interconversion through operation of enzyme 5-phospho-β-D-ribosylamine:diphosphate phospho-α-D-ribosyl-transferase (glutamate-
amidation reaction).
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FIGURE 9 | Time course 13C NMR spectra of perfused DLCL2 lymphoma cells and in vivo tumors upon rapamycin treatment. (A) Perfused DLCL2 cells
in 9.4T/8.9 cm vertical bore Varian NMR spectrometer. 4108 cells were encapsulated in agarose and perfused in a 10mm diameter NMR perfusion chamber with
RPMI 1640 medium containing 5mM [1,6-13C2] glucose maintained under an atmosphere of 20% O2, 75% N2, 5% CO2 at 37°C. (B) In vivo 13C MRS spectra of a
nude mouse with 12mm DLCL2 tumor implanted in its flank. Spectra were measured before and after rapamycin treatment with seven consecutive doses (10mg/kg)
administered by oral gavage twice daily. During the study, 450mM [1,6-13C2] glucose was infused through the tail vein at variable infusion rates. Each spectrum was
acquired in 15min on a 9.4 T/31 cm spectrometer with a home-built 13mm loop-gap resonator.
The rate of lactate labeling has decreased, whereas the rate of
alanine labeling appears to have increased. Glutamate-C4 was
detectable and appears to have decreased after rapamycin treat-
ment, suggesting a decrease in TCA cycle flux. The glycogen peak
appears very small in both sets of spectra and seems to have been
diminished but not eliminated after treatment. These are among
the first in vivo spectra we or anyone else we are aware of have
reported. We are pursuing a number of strategies for improving
the resolution and S/N ratio. Obviously, higher magnetic fields
or cryoprobes would increase the sensitivity, but even with the
equipment at hand it is clearly feasible to obtain quantitative data
in vivo.
A computational analysis (Figure 10) of the time course
in vivo data from a mouse to a two-compartment non-steady-
state enzyme kinetic model generated total lactate production
and clearance rates (indicated in the figure caption). The model
included glycolysis, alanine production, and exchange of cytosolic
and vascular/interstitial lactate through MCT1 (the dominant
monocarboxylic acid transporter). The calculated fluxes indicate
a decrease in glycolytic metabolism caused by treatment with
rapamycin. Clearly a more comprehensive analysis, including
other metabolic pathways that contribute to lactate production
is required, but this demonstrates feasibility of our precise data
analysis approach.
LC-MS Studies of DLCL2 Tumor Cells
Preliminary studies of DLCL2 cells in suspension culture have
been initiated in Dr. Blair’s laboratory (Figure 11). Cells were
grown in batch culture. Harvested cells were spiked with [U-13C]
lactate, citrate, and succinate as internal standards. The extracted
metabolites were separated by a reverse-phase ion-paring chro-
matography and analyzed by MS. Note that these are steady-state
measurements, which only provide information about relative
fluxes. Kinetic data are required for absolute flux measurements.
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FIGURE 10 | Dynamic glycolysis model of subcutaneous DLCL2 in a
mouse. Fitting of LacC3 in vivo data vs. time. Triangle, pretreatment, and
circle, posttreatment. Total lactate production rate, Flac= 0.80mM/min
(pretreatment) and Flac=0.62mM/min (posttreatment). Clearance rates were
Fcl= 0.59mM/min (pretreatment) and Fcl= 0.56mM/min post-treatment
(non-steady-state condition). Rapamycin treatment affects mostly the lactate
production rate. The inset is a typical blood glucose input function used in the
model.
FIGURE 11 |Mass spectrometric data of intracellular metabolites.
DLCL2 tumor cells were treated with and without 200 nM rapamycin for 48 h.
Measurements were made at steady-state isotope exchange conditions
(n= 3 for each condition). *p<0.05, **p<0.01, ***p<0.001.
Significant changes are evident in levels of glycolytic metabo-
lites (glucose-6P, fructose-1,6-P, 2-phosphoglycerate, pyruvate,
and lactate), pentose shunt metabolites (6-phosphogluconate and
5-carbon phosphates), and TCA cycle (citrate, succinate, and
malate) (100, 101).
In view of the recent interest in glutamine metabolism of
tumors (71), preliminary studies were performed on DLCL2 cells
grown in culture with 4mM [U-13C] glutamine; after 6 h steady
TABLE 5 | Pathway activities for DLCL2 cells based on 13C LC-MS data.a
Pathway name Control Rapamycin P-value
Reductive carboxylation (cytosolic) 0.290.05 0.170.03 0.0235
Glutaminolysis 0.270.10 0.0140.02 0.0122
Mitochondrial pyruvate carrier 0.630.06 0.900.09 0.0124
Pyruvate dehydrogenase complex 0.600.07 0.560.05 0.466
Pyruvate carboxylase (mitochondrial) 0.0750.030 0.390.09 0.0045
De Novo fatty acid production 0.390.07 0.230.05 0.0322
aPresented as real parameter value error in terms of standard deviation (SD). Errors are
based on Monte Carlo simulations assuming Gaussian noise with 0 mean and σ= 0.01
for SD; synthetic renormalized steady-state mass-isotopomers fit by fragmented cumomer
model using Simplex.
state was achieved. A preliminary analysis fitted the LC-MS iso-
topomer data (aspartate, glutamate, lactate, malate, succinate,
citrate, and α-ketoglutarate, Mo, M1, : : :, Mn, n= number of car-
bons) to all the metabolic pathways included in the fragmented
cumomer model (Shestov et al., manuscript in preparation) (13,
48, 49). There was excellent agreement between observed and
calculated isotopomer levels (data not shown). Themetabolic net-
work includes all the pathways included in the bonded cumomer
model (Figure 1). Table 5 summarizes changes in flux through
various pathways for which there was adequate significance.
Rapamycin produced dramatic changes in RC (41% decrease),
glutaminolysis (95% decrease), MPC (50% increase) and PC
(520% increase). Clearly, further study of these effects is required,
but these data strongly suggest that multiple pathways are affected
and, potentially, may serve as key biomarkers of effective mTOR
inhibition.
CONCLUSION AND SUMMARY
We have for the first time formulated and validated a detailed
metabolic network model of tumor intermediary metabolism that
includes all the key pathways except glycogen and phospholipid
metabolism as well as serine–glycine one-carbon metabolism.
These pathways can be added in the future. We have demon-
strated that glutaminemetabolism, while critical to AA and nucle-
oside/tide production, makes minimal contribution to energy
production in DB-1 melanoma. Studies of FA metabolism
have been initiated and need to be advanced further. Aer-
obic glycolysis and oxidative metabolism contribute approxi-
mately equally to energy production in this tumor and proba-
bly contribute in similar proportions to energy production by
many tumors, with relative contributions of glycolysis being
modulated by oxygen supply in the local environment of the
tumor.
Using NHL as a model and rapamycin as a specific thera-
peutic agent, we have formulated a general strategy for moni-
toring therapeutic response of signal transduction. This strategy
includes preliminary exploratory non-invasive 13C MRS studies
of tumor in situ and ex vivo 13CMRS and LC-MS studies of tumor
metabolism to identify key pathways that are modified by treat-
ment of individual patients with specific inhibitors. Because of the
intrinsic low sensitivity of 13CMRS, a key goal of these exploratory
studies will be to identify biomarkers of therapeutic response that
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can be more readily studied by more sensitive methods, such as
1H MRS and CEST (102) and PET/CT. In this regard, lactate
appears to be a critical metabolite that plays a central role in a
number of key metabolic pathways susceptible to modulation by
signaling inhibitors. Dynamic nuclear polarization may also play
an important role, although the short lifetime of probes, such as
13C-labeled pyruvate, forces them to be employed at abnormally
high concentrations, which may modify the metabolic pathways
that are being monitored. Despite its intrinsically low sensitiv-
ity, 13C MRS of glucose, lipids as well as low molecular weight
metabolites, such as acetate and glutamine, should not be ignored,
especially in view of the increasing availability of high-field instru-
ments, such as 7 Ts, of which more than 60 are already available
at leading institutions throughout the world. These are likely to
soon gain FDA approval and will become much more useful as
body coils and other probes become more available. The recent
demonstration of the feasibility of ex vivo 13C MRS and LC-MS
analysis of tumor specimens that have been surgically excised (18,
19) in conjunction with the current in vivo 13CMRS study at 9.4 T
of human melanoma and lymphoma xenografts in mice point to
the feasibility of non-invasive human metabolic studies. Overall,
metabolic studies are likely to complement genomic studies of
human cancer in the near future.
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